ALLcrimesfood&drugstaxestelecomcommercehealthconservationtransportationagricultureveteransbrowse all titles »
0

42 U.S.C. § 284qPain research

submitted 82 years ago by Pub. L. 111-148 to r/title-42-THE-PUBLIC-HEALTH-AND-WELFARE · 664 words · no verdicts yet

in plain englishAI-generated · not legal advice

NIH's Director is encouraged to grow pain research through the Pain Consortium, which must give yearly research recommendations. The Secretary must also set up an Interagency Pain Research Coordinating Committee, with federal and public members, meeting at least once a year. This Committee must summarize pain research, find research gaps, and recommend how NIH can improve pain care, treatment, and coordination.

(a) Research initiatives. (1) The Director of NIH is encouraged to continue and expand — through the Pain Consortium — an aggressive program of basic and clinical pain research. (2) At least once a year, the Pain Consortium, consulting the Division of Program Coordination, Planning, and Strategic Initiatives, must recommend pain research initiatives to the Director, to be funded from the Common Fund or other available money. (3) "Pain Consortium" means the NIH's Pain Consortium, or a similar cross-NIH coordinating group the Secretary names for this purpose. (b) Interagency Pain Research Coordinating Committee. (1) Within 1 year of March 23, 2010, the Secretary had to establish, and must maintain as needed, the Interagency Pain Research Coordinating Committee, to coordinate pain-research efforts across HHS and other federal agencies. (2)(A) The Committee has voting members: up to 7 federal representatives from agencies doing pain research or treatment, plus 12 more members under subparagraph (B). (B) The Secretary appoints those 12: 6 non-federal scientists, physicians, or health professionals, and 6 members of the public representing research, advocacy, or service organizations for people with pain conditions. (C) The Secretary may also appoint nonvoting members as appropriate. (3) The voting members choose a chairperson, subject to the NIH Director's approval. (4) The Committee meets at the chairperson's call or the NIH Director's request, but at least once a year. (5) The Committee must: (A) summarize federal pain-care research advances, including best practices for non-drug treatments and non-addictive products; (B) identify critical research gaps in symptoms and causes of pain, diagnosis, prevention, treatment, and management (including non-drug and non-addictive options), and risk factors for substance use disorders among people with pain; and (C) recommend to the NIH Director how to avoid duplicated federal effort, how to share pain-care information, and how to build public-private research partnerships. (6) The Secretary must include the Committee's recommendations and any resulting actions in relevant reports to Congress. (7) The Secretary must review whether the Committee is still needed at least once every 2 years.
the actual law source: uscode.house.gov ↗public domain
(a) Research initiatives
(1) In general

The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain.

(2) Annual recommendations

Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 282a(c)(1) of this title for the Common Fund or otherwise available for such initiatives.

(3) Definition

In this subsection, the term “Pain Consortium” means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection.

(b) Interagency Pain Research Coordinating Committee
(1) Establishment

The Secretary shall establish not later than 1 year after March 23, 2010, and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the “Committee”), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research.

(2) Membership
(A) In general

The Committee shall be composed of the following voting members:

(i)

Not more than 7 voting Federal representatives appoint 1 by the Secretary from agencies that conduct pain care research and treatment.

(ii)

12 additional voting members appointed under subparagraph (B).

(B) Additional members

The Committee shall include additional voting members appointed by the Secretary as follows:

(i)

6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.

(ii)

6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.

(C) Nonvoting members

The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

(3) Chairperson

The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.

(4) Meetings

The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.

(5) Duties

The Committee shall—

(A)

develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;

(B)

identify critical gaps in basic and clinical research on—

(i)

the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;

(ii)

the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and

(iii)

risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and

(C)

make recommendations to the Director of NIH—

(i)

to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;

(ii)

on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and

(iii)

on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.

(6) Report

The Secretary shall ensure that recommendations and actions taken by the Director with respect to the topics discussed at the meetings described in paragraph (4) are included in appropriate reports to Congress.

(7) Review

The Secretary shall review the necessity of the Committee at least once every 2 years.

Source credit: (July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585; amended Pub. L. 115–271, title VII, § 7042, Oct. 24, 2018, 132 Stat. 4016.)

history & why it existsrecord from the source credit
  • 1944Enacted · Pub. L. 111-148 · 124 Stat. 585
  • 2018Amended · Pub. L. 115-271 · 132 Stat. 4016

A history note hasn’t been published yet. The record shows enactment by Pub. L. 111-148 on 1944-07-01.

all 0 arguments · sorted by: best

0/280

no arguments yet — make the first case